Aptus Pharma Ltd, incorporated in 2010, is a pharmaceutical company engaged in the marketing and distribution of finished formulations across multiple therapeutic areas. Its product portfolio covers antacids, antibiotics, anti-inflammatories, cardiology and antidiabetic medicines, neuropsychiatry drugs, nutraceuticals, dental care, and injectable parenterals. The business operates through four divisions—Aptus Pharma for acute therapies, Aptus CD Care for chronic therapies, Aptus Wellcare for wellness products, and Aptus Global for overseas markets. As of March 31, 2025, the company offered 194 formulations in more than eleven therapeutic segments, supported by warehousing facilities in Ahmedabad and a network of 125 distributors, managed by a sales team of 54 field staff.
Unlike traditional manufacturing companies, Aptus Pharma follows a contract manufacturing model. It does not own plants but collaborates with seven partner units through a mix of formal loan and license agreements and informal arrangements based on purchase orders. This asset-light approach allows the company to distribute a wide variety of dosage forms such as tablets, capsules, syrups, softgels, and suspensions. With 70 employees and a growing presence in both domestic and international markets, Aptus Pharma’s IPO offers investors insight into a distribution-driven pharmaceutical business with diversified product coverage.
For more details, visit the Aptus Pharma IPO page.
Aptus Pharma IPO Details and Objectives
Details
| Information
|
IPO Date
| September 23, 2025 to September 25, 2025
|
Issue Size
| 18,60,000 shares
(aggregating up to ₹13.02 Cr)
|
Price Band
| ₹65 to ₹70 per share
|
Lot Size
| 2000 shares
|
Listing At
| SME BSE
|
Market Maker
| Market-Hub Stock Broking Pvt.Ltd.
|
Purpose of the IPO
Capital Expenditure for Office Premises with furniture and Industrial Racks
Funding the working capital requirements of the company
General Corporate Purpose
Timeline of Aptus Pharma IPO
Event
| Date
|
---|
IPO Open Date
| Tue, Sep 23, 2025
|
IPO Close Date
| Thu, Sep 25, 2025
|
Tentative Allotment
| Fri, Sep 26, 2025
|
Initiation of Refunds
| Mon, Sep 29, 2025
|
Credit of Shares to Demat
| Mon, Sep 29, 2025
|
Tentative Listing Date
| Tue, Sep 30, 2025
|
Cut-off time for UPI mandate confirmation
| 5 PM on Thu, Sep 25, 2025
|
Pricing & Lot Size of Aptus Pharma IPO
Price Band for the IPO
Minimum Lot Size and Application Details
Application
| Lots
| Shares
| Amount
|
Individual investors (Retail) (Min)
| 2
| 4,000
| ₹2,80,000
|
Individual investors (Retail) (Max)
| 2
| 4,000
| ₹2,80,000
|
S-HNI (Min)
| 3
| 6,000
| ₹4,20,000
|
S-HNI (Max)
| 7
| 14,000
| ₹9,80,000
|
B-HNI (Min)
| 8
| 16,000
| ₹11,20,000
|
How to Apply for the Aptus Pharma IPO?
Online Application Process
Log in to Your Trading Account: Access your trading account through your broker’s platform.
Navigate to the IPO Section: Go to the IPO section to view active IPO listings.
Select Aptus Pharma IPO: Find "Aptus Pharma IPO" and click on the ‘Apply’ button.
Enter Application Details: Specify the number of lots (minimum lot size: 2000 shares) and the bid price within the range of ₹65 to ₹70 per share.
Provide Your UPI ID: Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.
Review and Submit: Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on September 25, 2025, to complete your application process.
Additional Read- How to Apply for the Aptus Pharma IPO?
Financial Health and Performance
Key Financial Metrics
Total Assets: Grew from ₹6.22 crore in FY23 to ₹21.92 crore as of March 2025.
Total income: Reached ₹24.64 crore in FY25.
Profit After Tax (PAT): Stood at ₹3.10 crore for March 2025.
Net Worth: Recorded at ₹6.97 crore in FY25.
Total Borrowing: Recorded at ₹10.36 crore (March 2025), growing steadily over the years.
EBITDA: Stood at ₹4.76 crore in March 2025.
Recent Performance and Growth Prospects
The company has shown consistent improvement in its overall asset base over the past few years.
Its income levels have reflected steady expansion, signalling strengthening operations.
Profitability has improved, highlighting efficient cost management and market presence.
The net worth position has strengthened, indicating a more stable financial base.
Borrowings have increased gradually, supporting business growth and expansion activities.
Operating performance has remained healthy, reflecting a sustainable earnings profile.
Investment Risks and Opportunities
Potential Risks of Investing in the IPO
The company relies on third-party manufacturers, which may expose it to risks related to quality, supply timelines, and dependency on external partners.
Expansion and growth depend on maintaining strong distribution networks and consistent demand across therapeutic areas, which could face challenges from market competition or regulatory changes.
Opportunities and Growth Potential
The business operates with an asset-light model, enabling it to diversify its product offerings across acute, chronic, and wellness segments without heavy investment in infrastructure.
Growing presence in both domestic and international markets positions the company to capture demand across multiple therapeutic areas and enhance long-term scalability.
Key Performance Indicator (KPI)
KPI
| Values
|
ROE
| 44.50%
|
ROCE
| 45.66%
|
Debt/Equity
| 1.49
|
RoNW
| 44.50%
|
EBITDA Margin
| 19.31%
|
Aptus Pharma IPO Registrar & Lead Managers
Registrar
| Lead Manager(s)
|
---|
Bigshare Services Pvt.Ltd.
| Interactive Financial Services Ltd.
|
Company Address of Aptus Pharma Ltd
Aptus Pharma Ltd. Ashutosh Buildcon, Opp. Slok - 2, Nr. Harikrupa Logistic Park, Aslali, Ahmedabad, Daskroi, Ahmedabad, Gujarat, 382427
Phone: +91 76004 27827
Email: info@aptuspharma.com
Website: https://aptus-pharma.com/
Conclusion
Aptus Pharma IPO provides an overview of a pharmaceutical company that works through a marketing and distribution-driven model. With divisions focused on acute therapies, chronic care, wellness, and exports, the business maintains a diverse product portfolio across multiple therapeutic areas. Its reliance on contract manufacturing allows for flexibility in production while keeping the business asset-light.
The IPO objectives include funding working capital needs, office-related expenditure, and general corporate purposes. Investors are presented with details on issue size, timelines, pricing, and application process, offering insight into the company’s structure and financial standing without ownership of manufacturing facilities.
Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Aptus Pharma IPO.